Thomas Decker

6PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 18, 2026
Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Patrick Marschner, Kai Ringwald, Marc Thill

|Mar 06, 2026
Real-world progression-free survival and overall survival in patients with HR+/HER2- advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.

Peter A Fasching, Cosima Brucker, Thomas Decker

|Dec 21, 2024
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Marc Thill, Mark-Oliver Zahn, Anja Welt

|Feb 22, 2023
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.

M Thill, M-O Zahn, A Welt

|May 18, 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.

Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen

|May 23, 2019
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.

Thomas Decker, Norbert Marschner, Axel Muendlein

Pageof 1

Frequent Collaborators

2 joint publications

Anja Welt

1 joint publications

Geoffrey J Lindeman

1 joint publications

Tharu M Fernando

1 joint publications

Steve McCune